Zero Candida Announces Plans to Complete Preclinical Studies for FDA Submission by Q3 2025

VANCOUVER, BC, January 06, 2025 /PRNewswire/ — Zero Candida Technologies, Inc. (TSXV: ZCT) (FSE: 9L2) (the “Company” or “ZCT”), an Israeli FemTech medical device company focused on revolutionizing women’s health, announces plans to complete preclinical studies for FDA submission by Q3 2025. In accordance with FDA requirements, the company is preparing to conduct a full preclinical study of its final human-use device in up to 24 additional sheep. 

Are you an angel?

Public Announcements

Zero Candida Commences Trading on OTCQB Market

VANCOUVER, BC, March 12, 2025 /PRNewswire/ — Zero Candida Technologies, Inc. (TSXV: ZCT) (OTCQB: ZCTFF) (FSE: 9L2) (the “Company” or “ZCT”), a FemTech medical device…

Moore Market analysis: Zero Candida potential market will reach over $2 Billion by 2030

VANCOUVER, BC, Feb. 3, 2025 /PRNewswire/ — A market analysis made by Moore Financial Consulting published today estimate the global market for Zero Candida Technologies,…

Zero Candida Announces Successful Listing on Frankfurt Stock Exchange and Details of Investor Webinar

VANCOUVER, BC, Jan. 16, 2025 /PRNewswire/ — Zero Candida Technologies, Inc. (TSXV: ZCT) (FSE: 9L2) (the “Company” or “ZCT”), an Israeli FemTech medical device company…